Both emphysema and chronic bronchitis are considered to be progressive lung diseases that fall under the general term COPD, or chronic obstructive pulmonary disease. COPD is marked by inflammation and narrowing of the airway walls, leading to decreased airflow in the lungs over time. Inflammation is the local response of the body to cell injury, characterized by irritation and thickening of the airways.
Asthma is a different lung disease, but can sometimes be mistaken for COPD because of similar symptoms, such as persistent coughing and shortness of breath. However, COPD and asthma are associated with different triggers and risk factors. People with asthma are more likely to have allergies, while people with COPD are more likely to have a history of smoking.
If you have any questions about your diagnosis, be sure to ask your doctor.
COPD: SYMBICORT 160/4.5 mcg is used long-term to improve symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, for better breathing and fewer flare-ups.
Asthma: SYMBICORT is for the treatment of asthma in patients 6 years and older whose asthma is not well-controlled with an asthma-control medicine such as an inhaled corticosteroid (ICS) or whose asthma warrants treatment with both an ICS and a long-acting beta2-adrenergic agonist (LABA).
SYMBICORT is not used to relieve sudden breathing problems and will not replace a rescue inhaler.Please see full Prescribing Information and Patient Information, and discuss with your doctor.
You may report side effects related to AstraZeneca products by clicking here.
This site is intended for US consumers only.
The information on this Web site should not take the place of talking with your doctor or health care professional. If you have any questions about your condition, or if you would like more information about SYMBICORT, asthma, or COPD, talk to your doctor or pharmacist. Only you and your doctor can decide if SYMBICORT is right for you.